Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT07496463
Phase
PHASE2
Status
Enrolling By Invitation

Conditions

  • Obesity
  • Pseudohypoparathyroidism Type 1a

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Setmelanotide — DRUG
    Setmelanotide will be prescribed at the standard initial dose of 2 mg SC daily. The treatment will be uptitrated at the 2-Week visit to 3 mg SC daily if tolerated. We will continue this maximal dose for a period of 6 months.

Study Details

The investigators plan to test the efficacy and safey of 6-months of open-label setmelanotide to treat obesity in a single patient with pseudohypoparathyroidism type 1a due to a GNAS mutation.

Key Dates

First listed
Mar 27, 2026
Start date
Jul 21, 2026
Status verified
Jul 2026
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
1 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Patient with pseudohypoparathyroidism type 1a
    A preselected patient with obesity related to pseudohypoparathyroidism type 1a.

Primary Outcome Measure

Greater than or Equal to 5% Weight loss [ Time Frame: Baseline to 6 Months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114-

Find similar trials in Boston, MA

Nationwide
Obesity / overweight trialsEndocrinology trialsMetabolic health trialsWeight loss trials
By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Massachusetts General Hospital· Boston, MA

Related Studies